Pharmamarketeer

Bayer’s Xarelto receives US FDA nod to treat coronary artery disease

The US Food and Drug Administration (FDA) has approved rivaroxaban (Xarelto), 2.5 mg twice daily, plus aspirin low dose once daily to reduce the risk of major cardiovascular events including cardiovascular (CV) death, heart attack or stroke in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD).

Reageer

Medhc-fases-banner
Advertentie(s)